HeartFlow Announces New Reimbursement Code and Increased Payment for FFRCT
Category I CPT code for Fractional Flow Reserve derived from Computed Tomography will provide broader access to HeartFlow’s AI-powered technology, a standard of care for evaluating and treating coronary artery disease
MOUNTAIN VIEW, Calif. – January 23, 2024 — HeartFlow, Inc., a leader in non-invasive integrated artificial intelligence (AI) heart care solutions, announced FFRCT was transitioned to a Category I Current Procedural Terminology (CPT®) code beginning January 1, 2024.
The new code, designated by The American Medical Association (AMA), supports FFRCT as the standard of care in assessing patients with suspected coronary artery disease (CAD). In the hospital setting, CMS increased payment for the FFRCT service by ~7% for 2024. The new code can be used for hospital outpatient, physician offices, or imaging centers. As part of converting to a Category I code, relative value units (RVUs) have been assigned to FFRCT , which provides payment to physicians for the service.
In response to increased utilization of the HeartFlow FFRCT Analysis service, strong evidence for its clinical value and inclusion in updated practice guidelines, the American College of Cardiology (ACC), American College of Radiology (ACR), and the Society of Cardiovascular Computed Tomography (SCCT) petitioned the AMA for the Category I CPT code, which will replace four existing Category III CPT codes. In addition, the AMA released guidance for appropriate use of the new FFRCT code in the CPT® Changes 2024: An Insider’s Viewbook which describes the covered service as allowing the physician to1:
HeartFlow’s FFRCT Analysis meets the AMA Guidance for the Category 1 code to allow physicians to enable patient care compliantly.
“We appreciate the American Medical Association’s decision to assign FFRCT a Category I CPT code, a decision backed by years of research that highlights the positive impact FFRCT can have on the diagnosis and eventually treatment of patients with coronary artery disease,” said John Farquhar, CEO of HeartFlow. “This recognition emphasizes the value and importance of FFRCT Analysis to help clinicians accurately diagnose CAD in patients. Better reimbursement for hospitals leads to improved accessibility to this technology, which is a win for everyone involved, most notably patients.”
HeartFlow remains dedicated to reshaping cardiovascular care and ensuring that hospitals have access to comprehensive, accurate, and efficient solutions in precision coronary care. HeartFlow’s suite of non-invasive technologies helps clinicians identify stenoses in the coronary arteries (RoadMap™ Analysis), assess coronary blood flow (FFRCT Analysis), and characterize and quantify coronary atherosclerosis (Plaque Analysis).
HeartFlow is transforming precision coronary care with the only AI-powered non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guidelines, HeartFlow continues to advance the diagnosis and management of CAD. HeartFlow’s suite of non-invasive technologies includes its FFRCT Analysis, RoadMap™Analysis, and Plaque Analysis. To date, more than 500 peer-reviewed publications have validated our approach and, more importantly, our technologies have helped clinicians diagnose and manage over 250,000 patients. For more information, visit www.heartflow.com and connect on Twitter and LinkedIn.
1 From AMA CPT Changes 2024. CPT Copyright 2022 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.